"Breakthrough Cancer Drug Targets Aggressive Form of Deadly Disease"
The U.S. FDA has approved a new drug regimen for metastatic pancreatic adenocarcinoma, an aggressive form of cancer with a poor prognosis. The regimen, which includes Onivyde along with other medications, has shown significant improvements in survival rates and response rates in a randomized, controlled trial. While some experts view this as a useful new tool, others believe it does not represent meaningful progress and is substantially more expensive than the existing standard medication. The most commonly reported side effects of Onivyde include gastrointestinal upset, and proactive management is crucial.
